Use of Bisphosphonates, Calcium and Vitamin D for Bone Demineralization in Patients with Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome: A Systematic Review and Meta-Analysis of Clinical Trials
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The present study performed a systematic review and meta-analysis of clinical trials using bisphosphonates for bone demineralization in human immunodeficiency virus (HIV) patients. Methods: A comprehensive literature search was performed from January 2004 to January 2020 considering the bone mineral density (BMD) of the lumbar spine (LS) as the main outcome. Out of 214 titles that met criteria, 9 studies fulfilled the selection criteria. Results: A total of 394 patients were identified, and they were allocated into 2 groups: the intervention group (200 patients), to whom a combination of alendronate or zoledronate with calcium and vitamin D was administered; and control group (194 patients), to whom only calcium and vitamin D was administered. Clinical profile and indicators of bone metabolism of the participants were evaluated regarding effect size, homogeneity, and consistency. No substantial heterogeneity between the groups was found for the baseline variables, and there was high consistency to the main outcome. The meta-analysis shows a significant difference in post-treatment BMD, favoring the intervention over the control treatment. The intervention improved LS density up to 0.227 g/cm², raising the average to the levels of general population. Adverse effects related to intervention were fever immediately after zoledronate administration and gastrointestinal complaints during alendronate usage. Other adverse effects were barely reported and poorly connected to intervention by studies’ authors, despite all of them have been successfully resolved. Conclusions: This study provides evidence that BMD post-treatment is better in HIV patients who used bisphosphonates combined with calcium and vitamin D.
Abstract
Background: The present study performed a systematic review and meta-analysis of clinical trials using bisphosphonates for bone demineralization in human immunodeficiency virus (HIV) patients. Methods: A comprehensive literature search was performed from January 2004 to January 2020 considering the bone mineral density (BMD) of the lumbar spine (LS) as the main outcome. Out of 214 titles that met criteria, 9 studies fulfilled the selection criteria. Results: A total of 394 patients were identified, and they were allocated into 2 groups: the intervention group (200 patients), to whom a combination of alendronate or zoledronate with calcium and vitamin D was administered; and control group (194 patients), to whom only calcium and vitamin D was administered. Clinical profile and indicators of bone metabolism of the participants were evaluated regarding effect size, homogeneity, and consistency. No substantial heterogeneity between the groups was found for the baseline variables, and there was high consistency to the main outcome. The meta-analysis shows a significant difference in post-treatment BMD, favoring the intervention over the control treatment. The intervention improved LS density up to 0.227 g/cm², raising the average to the levels of general population. Adverse effects related to intervention were fever immediately after zoledronate administration and gastrointestinal complaints during alendronate usage. Other adverse effects were barely reported and poorly connected to intervention by studies’ authors, despite all of them have been successfully resolved. Conclusions: This study provides evidence that BMD post-treatment is better in HIV patients who used bisphosphonates combined with calcium and vitamin D.
참고문헌 (41)
- Hoy JF, "Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START bone mineral density substudy, a randomized trial", J Bone Miner Res, 32, pp.1945~1955 (2017)
- Amorosa V, "Bone disease and HIV infection", Clin Infect Dis, 42, pp.108~114 (2006)
- Saccomanno MF, "Bone disease in HIV infection", Clin Cases Miner Bone Metab, 8, pp.33~36 (2011)
- Althoff KN, "HIV and ageing : improving quantity and quality of life", Curr Opin HIV AIDS, 11, pp.527~536 (2016)
- Peck WA, "Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis", Am J Med, 94, pp.646~650 (1993)
- World Health Organization, "WHO scientific group on the assessment of osteoporosis at primary health care level", World Health Organization, ~ (2004)
- Ofotokun I, "HIV-1 infection and antiretroviral therapies : risk factors for osteoporosis and bone fracture", Curr Opin Endocrinol Diabetes Obes, 17, pp.523~529 (2010)
- Dalla Grana E, "Relationship between vertebral fractures, bone mineral density, and osteometabolic profile in HIV and hepatitis B and C-infected patients treated with ART", Front Endocrinol(Lausanne), 10, pp.302~ (2019)
- Premaor MO, "The hidden burden of fractures in people living with HIV", JBMR Plus, 2, pp.247~256 (2018)
- Sharma A, "Frailty predicts fractures among women with and at-risk for HIV", AIDS, 33, pp.455~463 (2019)
- Guaraldi G, "Cost of noninfectious comorbidities in patients with HIV", Clinicoecon Outcomes Res, 5, pp.481~488 (2013)
- McComsey GA, "Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV", AIDS, 21, pp.2473~2482 (2007)
- Mondy K, "Alendronate, vitamin D, and calcium for the treatment of osteopenia", osteoporosis associated with HIV infection, 2005, pp.38, 426~431
- Guaraldi G, "Alendronate reduces bone resorption in HIV-associated osteopenia", osteoporosis, 2004, pp.5, 269~277
- Rozenberg S, "Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120)", AIDS Res Hum Retroviruses, 28, pp.972~980 (2012)
- Natsag J, "Vitamin D, osteoprotegerin", receptor activator of nuclear factor-kappaB ligand (OPG, HIV Med, pp.2016, 17[DOI]
- Negredo E, "Comparison of two different strategies of treatment with zoledronate in HIV-infected patients with low bone mineral density : single dose versus two doses in 2 years", HIV Med, 16, pp.441~448 (2015)
- Bolland MJ, "Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men : a randomized controlled trial", J Clin Endocrinol Metab, 92, pp.1283~1288 (2007)
- Huang J, "A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis", AIDS, 23, pp.51~57 (2009)
- Higgins JPT, "Cochrane handbook for systematic reviews of interventions version 5.1.0" (2011), The Cochrane Collaboration
- Moher D, "Items de referencia para publicar Revisiones Sistemáticas y Metaanálisis : La Declaración PRISMA", Rev Esp Nutr Hum Diet, 18, pp.172~181 (2014)
- Pepe J, "Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study", Endocrine, 47, pp.456~462 (2014)
- Cotter AG, "Relative contribution of HIV infection, demographics and body mass index to bone mineral density", AIDS, 28, pp.2051~2060 (2014)
- Young B, "Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006", Clin Infect Dis, 52, pp.1061~1068 (2011)
- Torti C, "High prevalence of radiological vertebral fractures in HIV-infected males", Endocrine, 41, pp.512~517 (2012)
- Güerri-Fernandez R, "HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study", J Bone Miner Res, 28, pp.1259~1263 (2013)
- Shiau S, "Incident fractures in HIV-infected individuals : a systematic review and meta-analysis", AIDS, 27, pp.1949~1957 (2013)
- Borderi M, "Prevalence of sub-clinical vertebral fractures in HIV-infected patients", New Microbiol, 37, pp.25~32 (2014)
- Yin MT, "Fracture prediction with modified-FRAX in older HIV-infected and uninfected men", J Acquir Immune Defic Syndr, 72, pp.513~520 (2016)
- Kanis JA, "FRAX(®)with and without bone mineral density", Calcif Tissue Int, 90, pp.1~13 (2012)
- Brown TT, "Challenges in the management of osteoporosis and vitamin D deficiency in HIV infection", Top Antivir Med, 21, pp.115~118 (2013)
- Castronuovo D, "Bone disease in the setting of HIV infection : update and review of the literature", Eur Rev Med Pharmacol Sci, 17, pp.2413~2419 (2013)
- Reid IR, "Effects of vitamin D supplements on bone mineral density : a systematic review and meta-analysis", Lancet, 383, pp.146~155 (2014)
- Hileman CO, "Bone loss in HIV : a contemporary review", Curr Opin Endocrinol Diabetes Obes, 22, pp.446~451 (2015)
- Gallagher JC, "Vitamin D and aging", Endocrinol Metab Clin North Am, 42, pp.319~332 (2013)
- Curtis EM, "Prenatal calcium and vitamin D intake, and bone mass in later life", Curr Osteoporos Rep, 12, pp.194~204 (2014)
- Lips P, "Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial", Ann Intern Med, 124, pp.400~406 (1996)
- Meyer HE, "Can vitamin D supplementation reduce the risk of fracture in the elderly? A randomized controlled trial", J Bone Miner Res, 17, pp.709~715 (2002)
- Vieth R, "Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults", J Steroid Biochem Mol Biol, 89-90, pp.575~579 (2004)
- Ryom L, "Essentials from the 2015 European AIDS Clinical Society(EACS)guidelines for the treatment of adult HIV-positive persons", HIV Med, 17, pp.83~88 (2016)
- Ofotokun I, "A single-dose zoledronic acid infusion prevents antiretroviral therapy-induced bone loss in treatment-naive HIV-infected patients : A phase IIb trial", Clin Infect Dis, 63, pp.663~671 (2016)